Article
DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion push
Strong Bullish
88.6
−100 Bearish
0
+100 Bullish
Investing.com -- Genmab reported a 25% year-on-year increase in first-quarter revenue for 2026, driven by strong royalty income from blockbuster cancer drug DARZALEX and multiple sclerosis treatment Kesimpta, as the Danish biotech company continued investing heavily in its late-stage oncology pipeline.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
finance.yahoo.com
Published
May 7, 2026 · 2:46 pm
Article ID
NT72PSI
Original URL
Open source
Sentiment Signal
Strong Bullish
88.6
−100Neutral+100
More Like This